178 filings
Page 3 of 9
8-K
9s01ddmulyp2hjc3ouse
21 Mar 22
Other Events
4:05pm
8-K
nnngrbzibk96k
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
64111w sea7p4m
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am
8-K
tkhvyem
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
b1oiu1hpl
12 Nov 21
7 of 16 (44%) patients achieved best overall response of partial response
7:06am
8-K
i70pld
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
w563eeshz o8
28 Oct 21
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
4:06pm
8-K
dahl604slvfij
10 Sep 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
nlbu7xlm
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
lt0mr1orgmp0qd4zaw
5 Aug 21
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
7:06am
8-K
qcb1cws
15 Jul 21
Aravive Achieves Second Development Milestone from 3D Medicines
7:05am
8-K
0ug4lwl
24 Jun 21
Regulation FD Disclosure
7:07am
8-K
70qfwa6
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
08cq7fi
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
5bno02jqo5h9x9di
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
f03x5exk
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
o2nls vonc
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am
8-K
j9y53p w2ww17d
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
9v0ks3pz9d
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
1qcnwekvk 8k623rh
16 Feb 21
Entry into a Material Definitive Agreement
7:10am